MAB13415
Anti-MMP-9 Antibody, clone GE-213
clone GE-213, Chemicon®, from mouse
Sinónimos:
Gelatinase B, 92 kDa Type IV Collagenase
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
origen biológico
mouse
Nivel de calidad
forma del anticuerpo
purified antibody
tipo de anticuerpo
primary antibodies
clon
GE-213, monoclonal
reactividad de especies
human
fabricante / nombre comercial
Chemicon®
técnicas
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotipo
IgG1
Nº de acceso NCBI
Nº de acceso UniProt
Condiciones de envío
wet ice
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... MMP9(4318)
Especificidad
Under non-reducing conditions, it recognizes proteins of 92 kDa and 86 kDa which are identified as pro (latent) and active forms of matrix metalloproteinase-9 (MMP-9; also known as 92 kDa and collagenase IV or gelatinase B) of human MMP-9. MAB13415 reacts with the complex (~200 kDa) of MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1; Nikkari et al., 1996). It shows no cross-reaction with pro and active forms of MMP-2 (Nikkari et al., 1996). Clone GE-213 also shows very low reactivity to mouse MMP-9 proteins by western blot, but at high enough antibody and antigen concentrations some detection is possible. Mouse immunhistochemistry is untested. Cellular Localization: Peripheral cytoplasmic.
Inmunógeno
Purified human gelatinase B.
Aplicación
Anti-MMP-9 Antibody, clone GE-213 is an antibody against MMP-9 for use in IP, WB & IH.
Research Category
Cell Structure
Cell Structure
Research Sub Category
MMPs & TIMPs
MMPs & TIMPs
Western Blotting (non-reducing; Nikkari et al., 1996) (Use Ab at 1μg/mL for 2hrs at RT)
Immunohistochemistry (Acetone-fixed frozen; Hurskainen, 1996): 1:100 for 30 minutes at room temperature
Immunoprecipitation: 2-5 μg/mg protein lysate (use protein G to precipitate immune complex).
Inhibition of MMP-9 Activity: 2-4μg/mL (Visscher, 1994)
Optimal working dilutions must be determined by end user.
Immunohistochemistry (Acetone-fixed frozen; Hurskainen, 1996): 1:100 for 30 minutes at room temperature
Immunoprecipitation: 2-5 μg/mg protein lysate (use protein G to precipitate immune complex).
Inhibition of MMP-9 Activity: 2-4μg/mL (Visscher, 1994)
Optimal working dilutions must be determined by end user.
Ligadura / enlace
Replaces: 04-1150
Forma física
Format: Purified
Purified from ascites fluid by Protein G chromatography. Liquid in 10 mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.
Almacenamiento y estabilidad
Maintain at 2-8°C in undiluted aliquots for up to 12 months from date of receipt.
During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200μL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container′s cap.
During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200μL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container′s cap.
Nota de análisis
Control
POSITIVE CONTROL: Cytotrophoblastic columns, the endothelial and fibroblastic stromal cells of villi, and the large decidualized cells of decidual membrane in placenta (Hurskainen et al., 1996). Macrophages in arteries (Nikkari et al., 1996), and fibroblast, endothelial, and tumor cells in breast carcinomas (Soini et al., 1994; Visscher et al., 1994). Conditioned serum-free medium from (dexamethasone-treated) human fibrosarcoma HT-10801 (Nikkari et al., 1996) or endothelial HUVEC4 (Schnaper et al., 1993) cells.
POSITIVE CONTROL: Cytotrophoblastic columns, the endothelial and fibroblastic stromal cells of villi, and the large decidualized cells of decidual membrane in placenta (Hurskainen et al., 1996). Macrophages in arteries (Nikkari et al., 1996), and fibroblast, endothelial, and tumor cells in breast carcinomas (Soini et al., 1994; Visscher et al., 1994). Conditioned serum-free medium from (dexamethasone-treated) human fibrosarcoma HT-10801 (Nikkari et al., 1996) or endothelial HUVEC4 (Schnaper et al., 1993) cells.
Otras notas
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Información legal
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Cláusula de descargo de responsabilidad
Manufactured by Daiichi Fine Chemical Co., Ltd
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Código de clase de almacenamiento
12 - Non Combustible Liquids
Clase de riesgo para el agua (WGK)
WGK 2
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Themis R Kyriakides et al.
Matrix biology : journal of the International Society for Matrix Biology, 28(2), 65-73 (2009-04-22)
Matrix metalloproteinase- (MMP-9) is involved in processes that occur during cutaneous wound healing such as inflammation, matrix remodeling, and epithelialization, To investigate its role in healing, full thickness skin wounds were made in the dorsal region of MMP-9-null and control
Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9.
MacLauchlan, S; Skokos, EA; Meznarich, N; Zhu, DH; Raoof, S; Shipley, JM; Senior et al.
Journal of Leukocyte Biology null
Yifeng Jia et al.
Cancer research, 64(23), 8674-8681 (2004-12-03)
Integrins contribute to progression in many cancers, including breast cancer. For example, the interaction of alpha(5)beta(1) with plasma fibronectin causes the constitutive invasiveness of human prostate cancer cells. Inhibition of this process reduces tumorigenesis and prevents metastasis and recurrence. In
Jerzy Krupinski et al.
Vascular health and risk management, 3(4), 405-412 (2007-11-01)
Advanced atherogenesis is characterized by the presence of markers of enhanced prothrombotic capacity, attenuated fibrinolysis, and by clinical conditions associated with defective coagulation. Diabetes may be associated with enhanced lesion instability and atherosclerotic plaque rupture. Plaques obtained from 206 patients
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
Roy, R; Louis, G; Loughlin, KR; Wiederschain, D; Kilroy, SM; Lamb, CC; Zurakowski, D; Moses, MA
Clinical cancer research : an official journal of the American Association for Cancer Research null
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico